Results 71 to 80 of about 7,917 (182)

Prevalence of Vigabatrin-Induced Visual Field Loss

open access: yesPediatric Neurology Briefs, 2011
The magnitude of risk of vigabatrin-associated visual field loss and any clinical predictors of risk were determined by systematic review of 32 studies identified by electronic searches of the literature.
J Gordon Millichap
doaj   +1 more source

Outcomes of patients with post‐stroke epilepsy: A scoping review on quality of life, readmissions, costs, seizure recurrence, and medication adherence

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Post‐stroke epilepsy (PSE) affects ≈10% of patients with stroke and is associated with adverse health and economic outcomes. We aimed to review published literature on health and economic outcomes for patients with PSE, with a specific focus on quality of life, hospital readmissions, healthcare costs, seizure recurrence, and ...
Nega Dagnew Baye   +5 more
wiley   +1 more source

Vigabatrin Toxicity Mimicking Bilateral Thalamic Strokes [PDF]

open access: yes, 2023
A 20-month-old female with past medical history of tuberous sclerosis, epilepsy and infantile spams treated with vigabatrin presented for surveillance Magnetic Resonance Imaging (MRI) for multiple brain hamartomatous lesions and subependymal nodules. MRI
Lockard, Trevor, Rathore, Geetanjali
core  

Data‐Driven Insights into Hyperkinetic Disorders in Neurodevelopmental Syndromes and Epileptic Encephalopathies

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Childhood‐onset hyperkinetic movement disorders occur in a range of genetic conditions. Recently, there has been an increase in recognition of hyperkinetic movement disorders, mainly dystonia, chorea and dyskinesia, with monogenic conditions associated with neurodevelopmental delay (NDD) and also with developmental and epileptic ...
Hugo Morales‐Briceño   +6 more
wiley   +1 more source

Vigabatrin in Drug-Resistant Epilepsy

open access: yesPediatric Neurology Briefs, 1987
A double-blind, placebo-controlled, crossover study of oral Vigabatrin (2-3 g/d) as add-on therapy for 31 patients with drug-resistant seizures is reported from the Neurological Clinic, Univ of Bologna School of Med, Italy.
J Gordon Millichap
doaj   +1 more source

Oligogenic inheritance in epilepsy: A systematic exome‐wide analysis

open access: yesEpilepsia, Volume 67, Issue 11, Page 5990-6004, November 2026.
Abstract Objective Genetic factors contribute to the majority of epilepsies, but the exact genetic cause remains unknown in most patients. Incomplete penetrance and variable expressivity are frequent, and recent studies showed a burden of deleterious variants in epilepsy genes, suggesting a role for oligogenic inheritance.
Sarah Duerinckx   +192 more
wiley   +1 more source

Acute psychotic disorder associated to vigabatrin

open access: yes, 2000
Vigabatrin, a drug mainly used in the treatment of therapy-resistant epilepsy, has been associated to a large range of adverse effects, including acute psychotic disorders. The authors report the case of a 44-year-old patient with drug-resistant temporal
Xavier, Miguel   +3 more
core  

Vigabatrin for refractory partial epilepsy

open access: yes, 2013
Epilepsy is a common neurological condition which affects between 0.5% and 1% of the population. Approximately 30% of people with epilepsy do not respond to treatment with currently available drugs.
Hemming, Karla; id_orcid   +3 more
core   +1 more source

Vigabatrin vs Carbamazepine in Partial Seizures

open access: yesPediatric Neurology Briefs, 1999
The efficacy and tolerability of vigabatrin (VGB) and carbamazepine (CBZ) monotherapy were compared in an open long-term study in newly diagnosed partial seizures in children treated at the Infantile Neuropsychiatric Division of the Regional Pediatric ...
J Gordon Millichap
doaj   +1 more source

Efficacy and safety of pharmacological interventions for the treatment of cocaine use disorder: A systematic review and network meta‐analysis

open access: yesAddiction, Volume 121, Issue 11, Page 2897-2958, November 2026.
Abstract Background and aims Cocaine use disorder (CUD) is an increasingly widespread concern worldwide. Various pharmacological treatments have been investigated for CUD, but their efficacy remains unclear, and none have been licensed for treatment.
Craig Paterson   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy